| Document |
Document Title |
|
JP2019048851A |
To provide modified drugs for use in liposomal nanoparticles.Provided herein is a drug derivative suitable for loading into liposomal nanoparticle (LN) carriers. In some preferred aspects, the derivative comprises a drug with low water s...
|
|
JP2019508390A |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof:(In the formula, R1, R2, R3, R4aAnd R4b(As defined herein), methods of their manufacture, pharmaceutical compositions containing them...
|
|
JP2019507733A |
The present disclosure describes molecules that have pesticide efficacy against pests of the phylum Arthropods, Psocoptera, and C. elegans, processes that produce such molecules, intermediates used in such processes, and such molecules. ...
|
|
JP2019034943A |
To provide a novel compound useful as a pregenomic RNA capsid formation inhibitor useful for the treatment of hepatitis B virus (HBV) infection and related disease states.The compound is, for example, a compound represented by formula (X...
|
|
JP2019505483A |
The present invention relates to a polymerizable compound, a method for producing the polymerizable compound, an intermediate for producing the polymerizable compound, a liquid crystal (LC) medium containing the polymerizable compound, a...
|
|
JPWO2017170808A1 |
Provided is a method for efficiently producing a four-membered ring lactone in a higher yield in a carbonylation reaction of an epoxide using a heterogeneous catalyst that can be easily separated from a product and can be handled in air....
|
|
JPWO2017170859A1 |
An object of the present invention is to provide a compound that inhibits the collagen-binding function of HSP47, which is essential for the extracellular secretion of collagen. The present invention provides a bisaryl derivative represe...
|
|
JP2018199677A |
To provide a therapeutic compound and composition.There is provided an arylsulfonamide diaryl urea derivative compound, which is an inhibitor of mutated isocitrate dehydrogenase enzyme 1/2 (IDH1/2) and is useful for a treatment of cancer...
|
|
JP6409001B2 |
including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, and R8 are defined herein.
|
|
JP6402976B2 |
|
|
JP2018528159A |
Equation (I) Substituted aromatic sulfonamides, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for producing pharmaceutical compositions for treating or preventing a disease.
|
|
JP6397501B2 |
The present invention relates to a novel process for the preparation of a compound of the formula (I): and pharmaceutically acceptable acid addition salts thereof, which is useful for prophylaxis and treatment of respiratory syncytial vi...
|
|
JP2018527360A |
To widely provide a compound useful for treating cancer. In some embodiments, the invention provides a low molecular weight cytotoxic agent that has been chemically modified to include one or more moieties, such as a hydrophobic moiety. ...
|
|
JP2018525363A |
The present invention relates to substituted amide derivatives having dual pharmacological activity against both the sigma (σ) receptor and the μ-opioid receptor, methods of preparing such compounds, pharmaceutical compositions contain...
|
|
JP2018525341A |
Growth of cancer, viral infections and / or inflammatory disorders, etc. using compounds that regulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds, and thi...
|
|
JP6372060B2 |
|
|
JP6360500B2 |
The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in ...
|
|
JP2018516890A |
The present invention is a compound having the following formula (I): in the form of a base, hydrate or solvate for its use as a drug in the treatment of cancer in patients with liver damage. With respect to compounds that may be. [Chemi...
|
|
JP6347797B2 |
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
|
|
JPWO2017038870A1 |
An object of the present invention is to provide a compound having an inhibitory activity on discoidin domain receptor 1. The present invention provides a urea derivative represented by the following formula or a pharmacologically accept...
|
|
JP6336562B2 |
Proivded herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).
|
|
JP6337497B2 |
|
|
JP6329135B2 |
The present invention relates to the field of medical chemistry, and discloses a preparation method for three crystal forms of cabazitaxel, that is, ester compound crystalline form J of cabazitaxel, hydrate crystalline form G of cabazita...
|
|
JP6323144B2 |
To provide a polymerizable compound having high storage stability without causing precipitation of crystals or the like when added to a polymerizable composition and large refractive index anisotropy and to provide a polymerizable compos...
|
|
JP6319618B2 |
|
|
JP6313415B2 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
JP6309519B2 |
The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described ...
|
|
JP6304529B2 |
To provide a polymerizable compound that prevents the occurrence of crystal deposition or the like when added to a polymerizable composition and has high storage stability.This invention provides a compound represented by general formula...
|
|
JP2018506547A |
The integrated process herein provides improved carbon efficiency for processes based on coal or biomass gasification or steam methane reforming. Also provided are ethylene oxide carbonylation products, such as beta-propiolactone and suc...
|
|
JP2018504373A |
The present invention is a method for inhibiting, suppressing or preventing HBV infection in an individual who needs to inhibit, suppress or prevent HBV infection, and comprises administering to the individual a therapeutically effective...
|
|
JP6275690B2 |
Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising the same and methods of treating patients suffering from certain diseases and disorders response to the inhibition of KMO...
|
|
JP2018016546A |
To provide a novel oxetane compound capable of providing a cured resin excellent in heat resistance and flexibility.There is provided a trioxetane ether compound represented by the general formula (1) in the figure. (In the formula, R, R...
|
|
JP6266528B2 |
The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleyl...
|
|
JP6262743B2 |
The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3′, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods ...
|
|
JP6260532B2 |
|
|
JP6259814B2 |
A compound represented by general formula (1) (wherein R 1 represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or the like; R 2 represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or the like; R 3 ...
|
|
JP2017218391A |
To provide a polymerizable compound giving such properties when added to a solution comprising a polymerizable composition that the resultant polymerizable composition has high storage stability and can induce a liquid crystal phase alig...
|
|
JP6244856B2 |
|
|
JP6241654B2 |
|
|
JP2017193519A |
To provide a compound having cytostatic activity and anticancer activity.The invention provides a compound represented by general formula (1) in the figure, or a salt thereof, or a solvate of the compound or salt thereof. [In general for...
|
|
JP6217999B2 |
The present invention provides a polymerizable compound that reduces, for example, the likelihood of crystals precipitating in a polymerizable composition including the polymerizable compound and enables the polymerizable composition to ...
|
|
JP6218282B2 |
To provide a polymer having high conductivity and usable as a solid electrolyte for a secondary battery, and a monomer as a raw material of the polymer.There are provided an oxetane compound represented by the formula (1) and a solid ele...
|
|
JP6216417B2 |
The present invention relates to new taxane analogs useful for the treatment of cancer as well as methods for producing the same. The chemical compounds according to the present invention have the general Formula (I) wherein R 1 and R 2 ...
|
|
JP2017528432A |
The present invention relates to the cyanocycloalkylpenta-2,4-dienes, cyanocycloalkylpent-2-ene-4-ins, cyanoheterocyclic penta-2,4-dienes and cyanoheterocycles of the general formula (I). Ring penta-2-ene-4-ins or salts thereof [[XY], Q,...
|
|
JP2017525677A |
The present invention is a compound having the general formula (I), in which the variable RA, RAA, Subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D, and E have the meanings described herein, and provide com...
|
|
JP6189020B2 |
A resist composition having a resin having a structural unit represented by the formula (I), a resin being insoluble or poorly soluble in alkali aqueous solution, but becoming soluble in an alkali aqueous solution by the action of an aci...
|
|
JP2017523967A |
In the present invention, the general formula (I) [in the formula, [XY], Q, R1, R2, A1, A2, V, W, m and n have the definitions specified herein], the substituted vinylcyanocycloalkanol, alkynylcyanocycloalkanol, vinylcyanoheterocyclylalk...
|
|
JP6182510B2 |
The invention relates to a compound of formula:which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particula...
|
|
JP6182594B2 |
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammator...
|
|
JP6169100B2 |
N-arylamidine substituted trifluoroethyl sulfide derivatives (I) are new. N-arylamidine substituted trifluoroethyl sulfide derivatives of formula (I) are new. n : 0-2; either X1-X4 : cycloalkylalkyl, cycloalkyloxy, cycloalkyl-alkoxy, cyc...
|
